THETFORD MINES, QC, June 18, 2026 /CNW/ - KDA Group Inc. (TSXV: KDA) ("KDA" or the "Corporation"), a leader in innovative technological solutions for healthcare professionals, is pleased to announce the results of an independent evaluation of its digital platform Medherize, conducted by the Breast Disease Centre of CHU de Québec – Université Laval (Hôpital du Saint-Sacrement). Carried out among 243 patients with breast cancer on targeted oral therapies (CDK4/6 inhibitors) between September 2025 and March 2026, the evaluation demonstrates measurable benefits, for both patients and care teams.
Read more at newswire.ca
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
AN INDEPENDENT EVALUATION CONFIRMS THE CLINICAL AND ORGANIZATIONAL BENEFITS OF THE MEDHERIZE PLATFORM IN BREAST ONCOLOGY
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
